Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2025 04:30 ET | Source: Angelini Ventures

Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million

CoMind's optical brain sensing technology uses laser light delivered through a removable sensor to provide continuous, non-invasive brain monitoring without need for surgery Advancing brain health...
October 03, 2025 04:00 ET | Source: Angelini Ventures

Angelini Ventures Leads €12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company

Through its investment, Angelini Ventures aims to promote the expansion and acceleration of Serenis’ digital health and wellbeing services and amplify its leadership in delivering transformative...
July 10, 2025 05:10 ET | Source: Angelini Ventures

Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

- Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in...
June 11, 2025 02:30 ET | Source: Angelini Ventures

Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs First start-up company from Argobio’s...
May 14, 2025 10:00 ET | Source: Angelini Ventures

Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases

Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic...
May 06, 2025 02:00 ET | Source: Angelini Ventures

Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio Rome, Italy - 6 May 2025 –...
April 07, 2025 02:00 ET | Source: Angelini Ventures

Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director

Accomplished biotech investor with a track record of successful company-building and exits to lead Angelini Ventures’ international BioTech investment strategy Rome, Italy, 7 April 2025 – Angelini...
March 12, 2025 03:30 ET | Source: Angelini Ventures

Angelini Ventures leads €10 million Series A financing in Vantis, a Digital Care Innovation company

Strategic investment in digital health solutions addressing critical challenges in primary care and chronic disease management Rome, Italy, 12 March 2025 – Angelini Ventures, the corporate venture...
January 28, 2025 01:05 ET | Source: Angelini Ventures

Angelini Ventures co-leads €35 million oversubscribed Series B financing in Nobi, an AgeTech company, to expand AI-enabled technology across senior care facilities globally

Angelini Ventures’ investment in Nobi demonstrates its continued strategic focus on digital health and connected health devices and represents a significant opportunity to improve the wellbeing of...
January 08, 2025 02:00 ET | Source: Angelini Ventures

Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders

Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors Financing will support clinical development of Neumirna‘s...